Peripheral deposition of α1‐protease inhibitor using commercial inhalation devices
Authors:
- P. BrandPBP. Brand
- H. BeckmannHBH. Beckmann
- M. Maas EnriquezMEM. Maas Enriquez
- T. MeyerTMT. Meyer
- B. MüllingerBMB. Müllinger
- K. SommererKSK. Sommerer
- N. WeberNWN. Weber
- T. WeuthenTWT. Weuthen
- G. ScheuchGSG. Scheuch
- 1 August 2003
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 22 (2) , 263-267
Abstract
Patients with hereditary α1‐proteinase inhibitor (α1‐PI) deficiency are at risk of developing lung emphysema. To prevent the development of this disease, α1‐PI replacement therapyviainhalation may be a more convenient and effective therapy than the intravenous administration of the drug.In order to optimise this treatment approach, lung deposition of inhaled radiolabelled α1‐PI (Prolastin®) was studied using four different commercial inhalation devices (PARI‐LC Star®, HaloLite®, and AKITA® system in combination with LC Star® and Sidestream®) in six patients with α1‐PI deficiency and mild-to-severe chronic obstructive pulmonary disease.The time required to deposit 50 mg of the Prolastin® (5% solution) in the lung periphery was used as a measure for the efficiency of delivery. The time was calculated from measurements of total and peripheral lung deposition of the radiolabelled α1‐PI. This time was shortest for the AKITA® system (18–24 min) and significantly higher for the PARI‐LC Star® (44 min) and the HaloLite® (100 min).The higher efficiency of drug delivery using the AKITA® system is due to the fact that this device controls breathing patterns, which are optimised for each patient individually.Keywords
This publication has 14 references indexed in Scilit:
- ALVEOLAR DEPOSITION OF MONODISPERSE AEROSOL PARTICLES IN THE LUNG OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASEExperimental Lung Research, 2002
- COMPARISON OF CLEARANCE OF PARTICLES INHALED WITH BOLUS AND EXTREMELY SLOW INHALATION TECHNIQUESExperimental Lung Research, 2001
- Total Deposition of Therapeutic Particles During Spontaneous and Controlled InhalationsJournal of Pharmaceutical Sciences, 2000
- Alpha-1-antitrypsin labeling with technetium-99m for monitoring the deposition of alpha-1-antitrypsin in aerosol therapy.Nuclear Medicine and Biology, 1998
- Lung volumes and forced ventilatory flowsEuropean Respiratory Journal, 1993
- Strategies for aerosol therapy ofα 1-antitrypsin deficiency by the aerosol routeLung, 1990
- Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle sizeJournal of Aerosol Science, 1990
- Antitrypsin and EmphysemaJAMA, 1988
- Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with EmphysemaNew England Journal of Medicine, 1987
- Experimental determination of the regional deposition of aerosol particles in the human respiratory tractAIHA Journal, 1980